AG-013958

AG-013958 is a small molecule tyrosine kinase inhibitor developed by Pfizer for the treatment of age-related macular degeneration (AMD), specifically targeting choroidal neovascularization associated with wet AMD. Its mechanism of action involves inhibition of vascular endothelial growth factor receptors (VEGFRs), particularly FLT and KDR/VEGFR2, thereby blocking VEGF-mediated angiogenesis in the eye. The drug was designed to be administered via subtenon injection to achieve effective local concentrations with minimal systemic exposure. Development was discontinued after Phase I/II clinical trials for AMD[1][3][7].